Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Section 3 of 6

Product information and disease description

280 evidence topics · 111 sources

Product description

Phase of product development

Regulatory status: Submission planned; NDA submission planned by the end of 2026
Launch

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Generic name, chemical name, and identifiers
FieldQuoted record
International nonproprietary name (Latin)“obefazimodum”
International nonproprietary name (English)“obefazimod”
Chemical name“8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine”
Functional description“immunomodulator”
Molecular formula“C16H10ClF3N2O”
CAS registry number“1258453-75-6”
INN list“Proposed INN: List 125”
Brand name

No evidence found.

Dosage forms and strengths
Pharmaceutical forms in the EU paediatric investigation plan: hard capsule and an age-appropriate oral liquid
Commercial dosage form and strengths

No evidence found.

Average sales price and wholesale acquisition cost
Wholesale acquisition cost and average sales price

Not applicable.

American hospital formulary service (AHFS), or other drug classification
AHFS classification

No evidence found.

Indication
Pharmacology
Mechanism of action
Pharmacodynamics
Dextran sodium sulfate colitis in mice
Pharmacokinetics
Effect of food on exposure
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Special populations
Pregnancy: reports in ABTECT maintenance Part 1
EventPlacebo (N = 192)Obefazimod 25 mg (N = 193)Obefazimod 50 mg (N = 195)
Pregnancy“0”“0”“2 (1.1%)”
Drug/Drug, drug/disease interactions
Effects of other drugs on Obefazimod
Fluvoxamine, a CYP1A2 inhibitor: obefazimod exposure in healthy participants (Part B)
ParameterDay 1, obefazimod 50 mg aloneDay 11, obefazimod 50 mg with fluvoxamine 100 mg
Participants analyzed“25”“25”
Cmax, ng/mL, mean (SD)“23.2(12.5)”“33.4(19.0)”
AUC, h*ng/mL, mean (SD)“55.2(25.7)”“73.0(34.2)”
Effects of Obefazimod on other drugs
Caffeine, a CYP1A2 substrate: caffeine exposure with single and repeated obefazimod doses (Part A)
ParameterDay 1, caffeine 50 mg aloneDay 4, caffeine with obefazimod 50 mgDay 17, caffeine with obefazimod after 14 days of daily dosing
Participants analyzed“22”“22”“22”
Caffeine Cmax, ng/mL, mean (SD)“931(285)”“930(278)”“564(242)”
Caffeine AUC, h*ng/mL, mean (SD)“7420(4760)”“5460(2740)”“1560(719)”
Dosing and administration
Dosage
Administration
Access and distribution
Specialty pharmacy network and patient support program

No evidence found.

Co-prescribed/Concomitant therapies
Effect of Obefazimod on quality measures
Product-specific effect on quality measures

No evidence found.

Product comparison

Place of product in therapy

Disease description

Definition and etiology
Disease definition: chronic inflammation of the rectum and colon
Epidemiology
Incidence of Ulcerative colitis
Prevalence of Ulcerative colitis
United States: prevalence per 100,000 under alternative case definitions and enrollment periods
Natural history, survival, and mortality
Disease course: relapsing and remitting, with relapse in 70% to 80% by 10 years
Pathophysiology
Diagnosis
Biomarkers: fecal calprotectin, C-reactive protein, and serology
Clinical presentation - signs and symptoms
Long-term morbidity
Colectomy: 10% to 20% of patients require proctocolectomy for refractory disease
Burden of Ulcerative colitis
Humanistic burden and health-related quality of life
Disease control, flares, and emotional impact in the UC Narrative global survey of 2100 patients

“Surveys of patients with UC (self-reported diagnosis; n = 2100) and physicians (n = 1254) were completed across 10 countries by The Harris Poll between August 2017 and February 2018.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The majority of patients (82%) had moderate to severe UC (based on medication history; those who had only ever taken 5-aminosalicylates were excluded); 67% described their UC as controlled with few to no symptoms. On average, patients experienced 4.3 flares (standard deviation, 7.4) in the past year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Globally, the majority of patients with moderate to severe disease (84%) reported UC to be mentally exhausting; even patients with milder UC (75%) or patients who self-reported being in remission (82%) agreed. Most patients (65%) felt that UC controlled their life rather than them controlling their UC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients reported visiting the bathroom (for any reason, including to pass stool, air, blood, or mucus) a mean of 3.5 times (SD, 2.9) on their best day and 9.8 times (SD, 7.4) on their worst day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In total, 21% and 15% of patients self-reported receiving a diagnosis of anxiety or depression, respectively, although this finding varied by country.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Economic burden and healthcare resource utilization
Economic impact of Ulcerative colitis on families
Economic impact of diagnostic testing
Cost-effectiveness of fecal calprotectin screening before endoscopy for suspected inflammatory bowel disease in the United States

Approaches to treatment

Current treatment options and standard of care
Aminosalicylates
Remission at Week 8 in two placebo-controlled induction trials of delayed-release mesalamine tablets
DoseStudy 1 (n=262) n/N (%)Study 2 (n=255) n/N (%)
Mesalamine 2.4 g/day“30/88 (34)”“34/84 (41)”
Mesalamine 4.8 g/day“26/89 (29)”“35/85 (41)”
Placebo“11/85 (13)”“19/86 (22)”
Corticosteroids
Induction of remission in Studies 1 and 2 of budesonide extended-release tablets
Treatment groupStudy 1 n/N (%)Study 2 n/N (%)
Budesonide 9 mg“22/123 (17.9)”“19/109 (17.4)”
Budesonide 6 mg“16/121 (13.2)”“9/109 (8.3)”
Placebo“9/121 (7.4)”“4/89 (4.5)”
Thiopurines and methotrexate
Recommendations for immunomodulator monotherapy and combination therapy: AGA 2024 living guideline

“5. In adult outpatients with moderate-to-severe UC, the AGA suggests AGAINST using thiopurine monotherapy for induction of remission. [Conditional recommendation, very low certainty of evidence]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“6. In adult outpatients with moderate-to-severe UC in remission, the AGA suggests using thiopurine monotherapy, rather than no treatment, for maintenance of remission, typically induced by corticosteroids. [Conditional recommendation, low certainty of evidence]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“7. In adult outpatients with moderate-to-severe UC, the AGA suggests AGAINST using methotrexate monotherapy, for induction or maintenance of remission. [Conditional recommendation, low certainty of evidence]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“8. In adult outpatients with moderate-to-severe UC, the AGA suggests the use of infliximab in combination with an immunomodulator over infliximab or an immunomodulator alone. [Conditional recommendation, moderate certainty of evidence]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“9. In adult outpatients with moderate-to-severe UC, the AGA suggests the use of adalimumab or golimumab in combination with an immunomodulator over adalimumab, golimumab or immunomodulator monotherapy. [Conditional recommendation, low certainty of evidence]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Tumor necrosis factor inhibitors
Pivotal trial efficacy of infliximab, adalimumab, and golimumab: ACG 2025 guideline
Efficacy tiers by prior advanced-therapy exposure: AGA 2024 living guideline

“In patients who are naïve to advanced therapies, the AGA suggests using a higher efficacy medication (infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab) or an intermediate efficacy medication (golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab), rather than a lower efficacy medication (adalimumab).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In patients who have previously been exposed to one or more advanced therapies, particularly tumor necrosis factor-α (TNF) antagonists, the AGA suggests using a higher efficacy medication (tofacitinib, upadacitinib, ustekinumab) or an intermediate efficacy medication (filgotinib, mirikizumab, risankizumab, guselkumab), rather than a lower efficacy medication (adalimumab, vedolizumab, ozanimod, etrasimod).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Infliximab has a possibly important benefit in achieving remission compared with adalimumab, mirikizumab, tofacitinib, and filgotinib with a low certainty of evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Notably, there was no RCT for infliximab or golimumab in patients with prior exposure to biologics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Anti-integrin antibodies
Recommendations and meta-analysis for vedolizumab: ECCO 2026 guideline

“We recommend treatment with vedolizumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, low certainty of evidence] [Agreement: 100%]” (opens the source at this quote in a new tab)

“We recommend vedolizumab for the maintenance of remission in patients with ulcerative colitis who responded to induction therapy with vedolizumab [strong recommendation, moderate certainty of evidence] [Agreement: 100%]” (opens the source at this quote in a new tab)

“We suggest the use of vedolizumab rather than adalimumab for the induction and maintenance of remission in moderate-to-severe ulcerative colitis [weak recommendation, low certainty of evidence] [Agreement: 100%]” (opens the source at this quote in a new tab)

“Induction responders who subsequently received vedolizumab were more likely to achieve clinical remission than those receiving placebo after 52–60 weeks of follow-up [RR: 2.37; 95% CI: 1.74–3.23].” (opens the source at this quote in a new tab)

“Rates of SAEs in patients treated with vedolizumab were not significantly different from those receiving placebo [RR: 0.71; 95% CI: 0.39–1.30].” (opens the source at this quote in a new tab)

“In the subgroup analysis, the results were statistically significant in biologic-naive patients and only numerically superior in the biologic-exposed population.” (opens the source at this quote in a new tab)

Interleukin-12/23 inhibitors
Interleukin-23 p19 inhibitors
ECCO 2026 guideline: recommendations and risankizumab trial results

“We recommend treatment with mirikizumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]” (opens the source at this quote in a new tab)

“We recommend treatment with risankizumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]” (opens the source at this quote in a new tab)

“We recommend treatment with guselkumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]” (opens the source at this quote in a new tab)

“At week 12, risankizumab significantly improved clinical remission rates compared with placebo (20.3% vs 6.2%, respectively; adjusted between-group difference [BGD]: 14.0% [95% CI: 10.0–18.0%]; P < .001).” (opens the source at this quote in a new tab)

“In the maintenance trial, each dose of risankizumab significantly improved clinical remission rates compared with placebo (40.2% for 180 mg risankizumab and 37.6% for 360 mg risankizumab vs 25.1% for placebo, BGD for 180 mg risankizumab vs placebo: 16.3% [95% CI: 6.1–26.6%]; P < .001)” (opens the source at this quote in a new tab)

“SC guselkumab is also effective for induction of remission in UC; this indication is supported by the efficacy and safety results from the ASTRO program.” (opens the source at this quote in a new tab)

“Data for IL-23 antagonist dose escalation are minimal and require further evidence before broader implementation.” (opens the source at this quote in a new tab)

Janus kinase inhibitors
Pivotal trial results for tofacitinib and upadacitinib: ACG 2025 evidence summary

“In both trials, clinical remission at week 8 occurred in a significantly higher proportion of patients treated with tofacitinib 10 mg twice a day (BID) (18.5% and 16.6%, respectively) compared with those receiving placebo (8.2% and 3.6%, respectively).” (opens the source at this quote in a new tab)

“At 52 weeks, in the maintenance trial, 40.6% of patients treated with tofacitinib 10 mg BID and 34.3% of patients treated with 5 mg BID achieved remission compared with 11.1% of those treated with placebo.” (opens the source at this quote in a new tab)

“In the U-ACHIEVE induction study, 26% of patients treated with upadacitinib achieved clinical remission compared with 5% of patients receiving placebo (P < 0.0001). In the U-ACCOMPLISH trial, 34% of patients receiving upadacitinib achieved clinical remission at 8 weeks compared with 4% of patients on placebo (P < 0.0001).” (opens the source at this quote in a new tab)

“At the end of follow-up, clinical remission was achieved by a larger proportion of patients treated with upadacitinib 15 mg/d (42%) or 30 mg/d (52%) compared with placebo (12%; P < 0.0001 for both).” (opens the source at this quote in a new tab)

“Filgotinib is an additional JAK-1 selective inhibitor which has demonstrated efficacy in moderately to severely active UC and is approved for use for this indication in Europe (204). However, this therapy is not available in the United States.” (opens the source at this quote in a new tab)

Network meta-analyses: rankings of Janus kinase inhibitors
Sphingosine-1-phosphate receptor modulators
Mechanism and pivotal trial results: ACG 2025 evidence summary

“The small molecule S1P receptor modulators ozanimod and etrasimod have a mechanism of action that sequesters activated lymphocytes in lymph nodes in patients with UC and results in decreased cellular inflammation in the bowel and a corresponding decreased circulating lymphocyte count.” (opens the source at this quote in a new tab)

“At the end of 10 weeks, a larger proportion of patients receiving ozanimod achieved clinical remission (18.4%) compared with placebo (6.0%, P < 0.001)).” (opens the source at this quote in a new tab)

“At the end of the maintenance period, 37% of patients continuing ozanimod achieved clinical remission compared with 18.5% of patients receiving placebo (P < 0.001).” (opens the source at this quote in a new tab)

“In the ELEVATE UC 52 study, at the completion of 12 and 52 weeks of treatment, 27% and 32% of patients receiving etrasimod achieved clinical remission compared with 7% and 7% of patients treated with placebo (P < 0.0001 for both comparisons).” (opens the source at this quote in a new tab)

“Unlike all other modern pivotal trials for moderately to severely active UC which excluded patients with isolated proctitis, the pivotal trials for etrasimod included patients with isolated proctitis and demonstrated a clinical remission rate in these patients of 43.2% at week 12, compared with 13.6% with placebo (P < 0.001).” (opens the source at this quote in a new tab)

“Significant cardiovascular disease, severe untreated sleep apnea, cardiac conduction defects, and concomitant use of monoamine oxidase inhibitors contraindicate the use of ozanimod.” (opens the source at this quote in a new tab)

Calcineurin inhibitors
Colectomy
Limitations of current therapies
Summary: limitations of current therapies

A review states that the highest response to medical therapies “ranges from 30% to 60% in clinical trials”, and another review states that “10-20% of patients still require proctocolectomy for medically refractory disease.” The ACG 2025 guideline states that up to one-fifth of patients receiving anti-TNF agents may not respond initially and that “an additional 10%–15% may lose response every year”; the ECCO 2026 guideline reports that 40% of patients on vedolizumab maintenance lose response. Among 3,562 patients initiating advanced therapy, 47.8% remained steroid-free after 12 months, and mean UC-related costs in the 12 months after initiation were $42,579. The two oral classes carry restrictions: the tofacitinib label carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis, and both U.S. JAK inhibitor labels indicate them in ulcerative colitis after an inadequate response or intolerance to one or more TNF blockers (for upadacitinib, after at least one approved systemic therapy when TNF blockers are clinically inadvisable); the S1P receptor modulators require pre-treatment assessments, and the ACG 2025 guideline states that significant cardiovascular disease and cardiac conduction defects, among other conditions, contraindicate ozanimod. Biologics require injections or intravenous infusions, which Abivax describes as resulting in “patient inconvenience and burden”.

Place in treatment, anticipated use, and care setting
Summary: anticipated place in therapy

Obefazimod is investigational, and no labeled indication exists. Abivax describes its pre-NDA interaction with the FDA as concerning obefazimod “for the treatment of adults with moderately to severely active ulcerative colitis”. ABTECT-1 and ABTECT-2 enrolled participants with a modified Mayo score of 5 or more who had an inadequate response, loss of response, or intolerance to at least one prior therapy, including corticosteroids, immunosuppressants, biologics, S1P receptor modulators, or JAK inhibitors, with no upper limit; 602 of 1,272 participants (47.3%) had a prior inadequate response to an advanced therapy. Obefazimod is taken orally once daily, whereas the IL-23 p19 inhibitors require intravenous induction (or subcutaneous induction for guselkumab) and subcutaneous maintenance.

Abivax states that it hopes “to position obefazimod as a potential first-line advanced therapy” and that there is no guarantee it would be approved for that use. Abivax estimates that approximately 300,000 moderate-to-severe U.S. patients, out of an estimated 500,000, are on conventional therapy or steroids only, and its research reported that physicians would likely initiate obefazimod in this population “where reluctance to advanced therapies hinder their use.” A Wedbush analyst noted that a boxed warning would limit commercial differentiation against JAK inhibitors.

The AGA 2024 guideline suggests early use of advanced therapies rather than gradual step-up after 5-aminosalicylate failure, and ranks therapies by efficacy separately for advanced therapy-naive and -exposed patients. The ECCO 2026 guideline recommends no treatment or class over another as first-line or subsequent therapy, apart from vedolizumab over adalimumab. The ACG 2025 guideline did not use indirect or post hoc data for its positioning recommendations and states that third-party payers and step therapy requirements “should not come between the patient and their healthcare team”. The BSG 2025 guideline provides no hierarchy. In a cohort of patients newly diagnosed with ulcerative colitis in 2019 to 2023, cumulative 1-year and 5-year use of advanced therapy was 27% and 38%.

Guideline sequencing: early advanced therapy and absence of a hierarchy
Heterogeneity of treatment effect
Summary: response by prior advanced therapy exposure

In the pooled ABTECT induction trials, 47.3% of participants had a prior inadequate response to an advanced therapy (AT-IR). The placebo-adjusted difference in clinical remission at week 8 with obefazimod 50 mg was 10.1% in participants with AT-IR and 22.4% in those without; with 25 mg, the difference was lower than with 50 mg in participants with AT-IR, and the two doses performed similarly in participants without AT-IR. In participants with prior JAK inhibitor failure, the pooled placebo-adjusted difference in clinical response with 50 mg was 34%. In the maintenance trial, clinical remission at Week 52 occurred in 72 of 117 (25 mg) and 62 of 105 (50 mg) participants against 15 of 120 with placebo among AT-IR-naive participants, and in 26 of 76 and 38 of 90 against 5 of 72 among participants with prior AT-IR. In the phase 2b open-label maintenance study, clinical remission at week 96 was 63.8% in participants naive to biologics or JAK inhibitors, and 38.8% of those with prior inadequate response were in clinical remission at both weeks 48 and 96. The same direction of effect is reported for comparators: the ACG 2025 guideline states that patients have higher response and remission rates with their first therapies than after failure of other advanced therapies, and the AGA 2024 guideline places different agents in its higher-efficacy tier for advanced therapy-naive and -exposed patients. In a 2026 network meta-analysis of induction trials, obefazimod and upadacitinib showed the highest efficacy in AT-naive patients, and upadacitinib, ustekinumab, and tofacitinib ranked highest in AT-experienced patients. All obefazimod subgroup p-values are nominal.

Obefazimod induction: efficacy with and without prior inadequate response to advanced therapy

“Among pts who participated in ABTECT‐1, ABTECT‐2, and the pooled analysis, 45.3% (288/636), 49.4% (314/636), and 47.3% (602/1272) were AT‐IR‐Yes, respectively; 54.7% (348/636), 50.6% (322/636), 52.7% (670/1272) were AT‐IR‐No.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In ABTECT‐1, ABTECT‐2, and pooled, a higher proportion of the AT‐IR‐Yes subgroup receiving Obe‐50 achieved all efficacy measures relative to PBO including clinical remission (Obe‐50‐PBO difference: ABTECT‐1 12.7%, p = 0.0039; ABTECT‐2 7.6%, p = 0.0652, pooled 10.1%, p = 0.0009).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the AT‐IR‐Yes subgroup, the difference from PBO across all efficacy measures was lower for pts receiving Obe‐25 relative to Obe‐50 (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the AT‐IR‐No subgroup, larger proportions achieved all efficacy measures relative to PBO including clinical remission (Obe‐50‐PBO difference: ABTECT‐1 25.0%, p < 0.0001; ABTECT‐2 19.4%, p = 0.0004; pooled 22.4%, p < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the subset of pts who failed JAKi, higher proportion of pts receiving Obe‐50 or Obe‐25 achieved clinical response versus PBO. The difference from PBO in clinical response for Obe‐25 and Obe‐50 was similar across lines of treatment, from AT‐IR‐No through 4+ AT‐IRs (Table).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Guideline efficacy tiers by prior advanced therapy exposure: AGA 2024

“In adult outpatients with moderate-to-severe UC who are naïve to advanced therapies, the AGA suggests using a HIGHER efficacy medication (infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib*, risankizumab, guselkumab) OR an INTERMEDIATE efficacy medication (golimumab, ustekinumab, tofacitinib*, filgotinib*, mirikizumab), rather than a LOWER efficacy medication (adalimumab).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In adult outpatients with moderate-to-severe UC who have previously been exposed to one or more advanced therapies, particularly TNF antagonists, the AGA suggests using a HIGHER efficacy medication (tofacitinib, upadacitinib, ustekinumab) OR an INTERMEDIATE efficacy medication (filgotinib, mirikizumab, risankizumab, guselkumab), rather than a LOWER efficacy medication (adalimumab, vedolizumab, ozanimod, etrasimod).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the Phase 3 randomized trial of ozanimod against placebo, ozanimod was significantly more effective than placebo in achieving clinical remission with rates of 23% (vs 7%) and 17% (vs. 8%) in biologic-naïve and single biologic-exposed patients. In contrast, in patients who had been on ≥2 biologics previously, ozanimod was no more effective than placebo (4% vs. 3%) in inducing clinical remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Care management intervention strategies
Obefazimod-specific care management program

No evidence found.

Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy
Summary: expected outcomes

STRIDE-II sets clinical remission and endoscopic healing as long-term treatment targets, adds absence of disability and restoration of quality of life, and sets symptomatic relief and normalization of serum and fecal markers as short-term targets; histological healing in ulcerative colitis is not a formal target. The ACG 2025 guideline recommends treating to endoscopic improvement (Mayo endoscopic subscore 0 or 1) to increase the likelihood of sustained steroid-free remission and to prevent hospitalization and surgery, and the ECCO 2026 guideline describes treat-to-target beyond steroid-free clinical remission as not yet conclusively validated. In the pooled ABTECT induction trials, the placebo-adjusted clinical remission rate at Week 8 with obefazimod 50 mg was 16.4%. In the ABTECT maintenance trial, clinical remission at Week 44 was 50.8% with 25 mg and 51.3% with 50 mg against 10.4% with placebo among 580 induction responders. At week 8 of induction, 37% of participants on 50 mg reported no bowel urgency against 18.1% on placebo. In Study 108, 68% (88/130) of participants were in clinical remission at week 144 after dose reduction to 25 mg. These obefazimod results come from press releases and congress presentations; no peer-reviewed full report of ABTECT has been published.